A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

PHASE4TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

April 25, 2025

Study Completion Date

April 25, 2025

Conditions
Palmoplantar PsoriasisGenital Psoriasis
Interventions
DRUG

Deucravacitinib

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (31)

1425

Local Institution - 0043, Ciudad Autónoma Buenos Aires

2000

Local Institution - 0042, Rosario

10003

Local Institution - 0002, New York

10075

Local Institution - 0008, New York

10128

Local Institution - 0062, New York

27157

Local Institution - 0001, Winston-Salem

44512

Local Institution - 0066, Boardman

46250

Local Institution - 0052, Indianapolis

77004

Local Institution - 0010, Houston

90404

Local Institution - 0004, Santa Monica

92708

Local Institution - 0015, Fountain Valley

85006-2722

Local Institution - 0050, Phoenix

90045-3606

Local Institution - 0009, Los Angeles

60077-1049

Local Institution - 0057, Skokie

46168-2792

Local Institution - 0053, Plainfield

20850-6243

Local Institution - 0029, Rockville

48202-3141

Local Institution - 0012, Detroit

08520-2505

Local Institution - 0005, East Windsor

44124-4005

Local Institution - 0055, Mayfield Heights

15213-3403

Local Institution - 0056, Pittsburgh

23502-3933

Local Institution - 0007, Norfolk

98012-1797

Local Institution - 0033, Mill Creek

C1428DZF

Local Institution - 0037, Ciudad Autónoma Buenos Aires

C1425DKG

Local Institution - 0034, Ciudad Autonoma Buenos Aires

L3Y 5G8

Local Institution - 0058, Newmarket

M3B 0A7

Local Institution - 0060, Toronto

H1Y 3L1

Local Institution - 0065, Montreal

H2X 2V1

Local Institution - 0054, Montreal

G1W 4R4

Local Institution - 0059, Québec

J7Z 7E2

Local Institution - 0061, Saint-Jérôme

S7K 2C1

Local Institution - 0064, Saskatoon

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY